clinical trial · NCT07215806
Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·phase1·completed·n = 20
HealthyEvobruitnibCombined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]
brief summary
The purpose of this study was to assess the effect of M2951 on the pharmacokinetics (PK) of a combined oral contraceptive \[Ethinyl estradiol/Norethisterone (EE/NET)\] in healthy female participants. * Study Duration: up to 46 days * Treatment Duration: Days 4 to 17 (14 days treatment with M2951); Days 1 and 15 (2 days treatment with Combined Oral Contraceptive \[COC\]) * Visit Frequency: Participants were resident in the Clinical Research Unit from Day -1 to Day 18.
started
Aug 24, 2022
primary completion
Nov 25, 2022
completion
Nov 25, 2022
last updated
Nov 14, 2025
official title
A Phase I, Open-Label, Multiple-Dose Study of the Effect of Evobrutinib on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Female Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol